Do Long-term Low-Dose Steroids Increase Cardiovascular Risk? Do Long-term Low-Dose Steroids Increase Cardiovascular Risk?
Cardiologist Mauricio Wajngarten discusses results of a study looking at the association between cardiovascular risk and the long-term use of corticosteroids in patients with inflammatory disease.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2021 Category: Consumer Health News Tags: Rheumatology Commentary Source Type: news
The first case of fungal endogenous endophthalmitis caused by Aspergillus nidulans : Diagnostic and therapeutic challenge.
Conclusion: Although uncommon, we must consider Aspergillus as the causative organism in apparently immunocompetent patients with history of recent systemic corticosteroids treatment, especially if they suffer a broncopulmonary disorder. Aspergillus is an aggressive organism so a high index of suspicion along with early diagnosis and prompt treatment is the key for better outcomes. We highlight A. nidulans as the causative agent as there are no other reported cases. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 14, 2021 Category: Consumer Health News Source Type: news
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the RP2D,...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC) Pha...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Clinical and Real-World Data Support Use of DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone (Rd). Updated data from the randomized Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patients were presented at the American Society of Hematology (ASH) 2021 Annual Meeting. Data from the GRIFFIN study will also be featured...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Basel, 07 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has extended the marketing authorisation for Actemra ®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.1 This decision comes just hours after the recommendation by the European Medicines Agency ' s (EMA) Committee for Medicinal Products for Human Use (CHMP), reflecting the urgent need for Actemra/RoActemra as a potential treatment option during the COVID-19 public health emergency. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2021 Category: Pharmaceuticals Source Type: news
Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Basel, 07 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has extended the marketing authorisation for Actemra ®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.1 This decision comes just hours after the recommendation by the European Medicines Agency ' s (EMA) Committee for Medicinal Products for Human Use (CHMP), reflecting the urgent need for Actemra/RoActemra as a potential treatment option during the COVID-19 public health emergency. (Source: Roche Media News)
Source: Roche Media News - December 7, 2021 Category: Pharmaceuticals Source Type: news
CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Basel, 06 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. A final decision regarding the approval of Actemra/RoActemra is expected from the European Commission in the near future. (Source: Roche Media News)
Source: Roche Media News - December 6, 2021 Category: Pharmaceuticals Source Type: news
CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Basel, 06 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. A final decision regarding the approval of Actemra/RoActemra is expected from the European Commission in the near future. (Source: Roche Investor Update)
Source: Roche Investor Update - December 6, 2021 Category: Pharmaceuticals Source Type: news
Risk of COVID-19 hospital admission among children aged 517 years with asthma in Scotland: a national incident cohort study, The Lancet Respiratory Medicine
National cohort study (n=752,867) found the risk of COVID-19 hospital admission was markedly increased in children with asthma with previous recent hospital admission (HR 6.40; 95% CI 3.27 –12.53) or ≥2 courses of oral corticosteroids (3.53; 1.87-6.67). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 2, 2021 Category: Consumer Health News Source Type: news
Can Corticosteroids Help in Kids' Eye and Throat Infections? Can Corticosteroids Help in Kids' Eye and Throat Infections?
Prospective studies are needed to clearly identify which patients will benefit.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 30, 2021 Category: Infectious Diseases Tags: Pediatrics News Source Type: news
Asthma Highlights From ACAAI 2021 Asthma Highlights From ACAAI 2021
From ACAAI 2021, Dr Sandhya Khurana reports on advances in asthma, including novel biologic therapies, burden of corticosteroid use, and racial differences in late effects of COVID-19.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
Anti-TNF Therapy Tied to Better Outcomes in IBD Patients With COVID-19 Anti-TNF Therapy Tied to Better Outcomes in IBD Patients With COVID-19
In patients with inflammatory bowel disease who contracted COVID-19 infection, anti-TNF therapies were associated with more favorable outcomes than corticosteroids or mesalamine in a systematic review and analysis.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 15, 2021 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
